Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03223389
Other study ID # CM-FAT-17
Secondary ID
Status Not yet recruiting
Phase N/A
First received July 18, 2017
Last updated July 24, 2017
Start date August 7, 2017
Est. completion date December 2018

Study information

Verified date July 2017
Source Hvidovre University Hospital
Contact Sten Madsbad, Professor
Phone +4538623032
Email sten.madsbad@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To investigate the effects of different fat metabolites on gut hormone secretion in gastric bypass operated subjects and BMI-matched controls.


Description:

Dietary triglycerides are hydrolyzed during digestion to two fatty acids and one 2-monoacyl glycerol. The study will investigate the effects of these different fat components on gut hormone secretion in gastric bypass operated patients and non-operated BMI-matched controls.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Gastric bypass operated patients:

Inclusion Criteria:

- Uncomplicated gastric bypass surgery performed minimum 12 months prior to study

Exclusion Criteria:

- Type 1 or 2 diabetes mellitus prior to or after gastric bypass surgery

- Pregnancy or breastfeeding

- Haemoglobin levels below 6,5 mM

- Gall bladder removal

Healthy control subjects:

Exclusion Criteria:

- Bariatric surgery or complicated upper abdominal surgery

- Gall bladder removal

- Pregnancy or breastfeeding

- Haemoglobin levels below 6,5 mM

- Co-morbidities or medicine significantly affecting glucose metabolism or appetite regulation

Study Design


Intervention

Dietary Supplement:
C-8 dietary oil
Ingestion of 13.15 g C-8 dietary oil providing 0.0216 mol of triglycerides.
Tricaprylin
Ingestion of 10.17 g tricaprylin providing 0.0216 mol of triglycerides.
Olive oil
Ingestion of 19 g olive oil providing 0.0216 mol of triglycerides.

Locations

Country Name City State
Denmark Dept. of Endocrinology Hvidovre

Sponsors (2)

Lead Sponsor Collaborator
Hvidovre University Hospital University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Within group difference in glucagon-like peptide-1 (GLP-1) secretion (evaluated by AUC above basal). Comparison of the GLP-1 responses (evaluated by AUC above basal) induced by the different oils. 0-240 min following fat ingestion.
Primary Within group difference in Gastric Inhibitory Peptide (GIP) secretion (evaluated by AUC above basal). Comparison of the GIP responses (evaluated by AUC above basal) induced by the different oils. 0-240 min following fat ingestion.
Primary Within group difference in cholecystokinin (CCK) secretion (evaluated by AUC above basal). Comparison of the CCK responses (evaluated by AUC above basal) induced by the different oils. 0-240 min following fat ingestion.
Secondary Between group comparison of GLP-1 secretion (evaluated by AUC above basal). GLP-1 secretion (evaluated by AUC above basal) in gastric bypass operated patients compared to BMI-matched control subjects for each of the oils. 0-240 min following fat ingestion.
Secondary Between group comparison of GIP secretion (evaluated by AUC above basal). GIP secretion (evaluated by AUC above basal) in gastric bypass operated patients compared to BMI-matched control subjects for each of the oils. 0-240 min following fat ingestion.
Secondary Between group comparison of CCK secretion (evaluated by AUC above basal). GIP secretion (evaluated by AUC above basal) in gastric bypass operated patients compared to BMI-matched control subjects for each of the oils. 0-240 min following fat ingestion.
Secondary Responses (evaluated by AUC above basal) of insulin within and between groups. 0-240 min following fat ingestion.
Secondary Responses (evaluated by AUC above basal) of C-peptide within and between groups. 0-240 min following fat ingestion.
Secondary Responses (evaluated by AUC above basal) of peptide YY (PYY) within and between groups. 0-240 min following fat ingestion.
Secondary Responses (evaluated by AUC above basal) of oxyntomodulin within and between groups. 0-240 min following fat ingestion.
Secondary Responses (evaluated by AUC above basal) of glucagon within and between groups. 0-240 min following fat ingestion.
Secondary Responses (evaluated by AUC above basal) of bile acids within and between groups. 0-240 min following fat ingestion.
Secondary Responses (evaluated by AUC above basal) of fibroblast growth factor 19 (FGF-19) within and between groups. 0-240 min following fat ingestion.
Secondary Responses (evaluated by AUC above basal) of lipid metabolites (triglyceride, cholesterol, fatty acids) within and between groups. 0-240 min following fat ingestion.
Secondary Responses (evaluated by AUC above basal) of neurotensin within and between groups. 0-240 min following fat ingestion.
Secondary Responses (evaluated by AUC above basal) of glucose within and between groups. 0-240 min following fat ingestion.
Secondary Between group comparison of differences in GLP-1 secretion (evaluated by AUC above basal). Differences in GLP-1 secretion (evaluated by AUC above basal) induced by the different oils in gastric bypass operated patients compared with differences in BMI-matched control subjects. 0-240 min following fat ingestion.
Secondary Between group comparison of differences in GIP secretion (evaluated by AUC above basal). Differences in GIP secretion (evaluated by AUC above basal) induced by the different oils in gastric bypass operated patients compared with differences in BMI-matched control subjects. 0-240 min following fat ingestion.
Secondary Between group comparison of differences in CCK secretion (evaluated by AUC above basal). Differences in CCK secretion (evaluated by AUC above basal) induced by the different oils in gastric bypass operated patients compared with differences in BMI-matched control subjects. 0-240 min following fat ingestion.
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A